Novitan SA
15.5 FTENovitan reported total assets of €30.2m at the end of the 2026 financial year (annual accounts filed with the NBB on 27 Oct 2026), with 15.5 full-time equivalents.
The score of Novitan shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2026
Change 2023 → 2026: Equity +3 % Total assets +159 % Headcount (avg FTE) +38 %
Accounts of the company itself (not consolidated).
The full file covers 10 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
Novitan's annual accounts
Filed annual accounts
- Year ended 31 Mar 2026filed on 27 Oct 2026
- Year ended 31 Mar 2025filed on 31 Oct 2025
- Year ended 31 Mar 2024filed on 29 Oct 2024
- Year ended 31 Mar 2023filed on 31 Oct 2023
- Year ended 31 Mar 2022filed on 07 Nov 2022
Novitan's financial analysis
- Solvency16.8%sector median: 46.0%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of Novitan
Novitan's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0446.988.767
- VAT number
- BE0446988767
- Peppol
- Registered · 0208:0446988767 · as of 10 Nov 2026
- Legal form
- SA
- Incorporated
- 30 Mar 1992
- Registered office
- 8500 Kortrijk
- Size
- Small · 15.5 FTE
- Latest accounts
- 2026 · filed on 27 Oct 2026
- Activity
- Wholesale of pharmaceutical and medical goods (NACE 46460)
Novitan (SA) has been based in Kortrijk since 1992, active in: wholesale of pharmaceutical and medical goods. For 2026, it reports a net profit of €2.33m and equity of €5.09m; its revenue is not published. With 15.5 full-time equivalents, it is a small enterprise by headcount. Its solvency stands at 16.8%, below the median of its sector (46.0%).
Guide: Reading Belgian SME accounts: the five figures that count →
Companies similar to Novitan
Companies in the same business, of comparable size and area, outside its group.
- Kenvue Belgium Wholesale of pharmaceutical and medical goods Antwerp · balance sheet €32.0m
- Haleon Belgium Wholesale of pharmaceutical and medical goods Zaventem · balance sheet €29.4m
- Vantive Belgium Wholesale of pharmaceutical and medical goods Braine-l'Alleud · balance sheet €23.3m
- Covetrus Wholesale of pharmaceutical and medical goods Beringen · balance sheet €37.1m
- sandoz Wholesale of pharmaceutical and medical goods Machelen (Brab.) · balance sheet €55.3m
- Menarini Benelux Wholesale of pharmaceutical and medical goods Machelen (Brab.) · balance sheet €48.6m
- Recordati Wholesale of pharmaceutical and medical goods Jette · balance sheet €20.8m
- Elekta Wholesale of pharmaceutical and medical goods Zaventem · balance sheet €13.1m
Frequently asked questions about Novitan
What is the revenue of Novitan?
Novitan files its accounts in a format where revenue is optional: it is not published for 2026.
What is the VAT number of Novitan?
In Belgium, the VAT number is the company number prefixed with BE: BE0446988767 for Novitan, if the company is VAT-registered. Its company number (CBE) is 0446.988.767.
Where is the registered office of Novitan?
According to the CBE register, the registered office of Novitan is in 8500 Kortrijk.
What is the equity of Novitan?
At the close of the 2026 financial year, the equity of Novitan amounts to 5,087,179 €, a solvency of 16.8% of total assets.
How many people work at Novitan?
15.5 full-time equivalents on average according to the 2026 social balance sheet.
Who manages Novitan?
The register lists 6 active mandates at Novitan. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of Novitan
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →